Early pembrolizumab plasma levels as a prognostic biomarker in real-world NSCLC patients
Pharmacological Research · 2026-06 · 228 · 108232
DOI: 10.1016/j.phrs.2026.108232 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Pharmacological Research, 2026-06. Verfasst von Cristina Martínez-Toledo und 27 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), Hospital Universitario Puerta de Hierro-Majadaho…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents, Immunological. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fundacion Cientifica de la Asociacion Espanola Contra el Cancer, Horizon 2020 Framework Programme, European Regional Development Fund.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.
- Pharmacy Unit, Hospital Universitario Severo Ochoa, Madrid, Spain; Universidad Alfonso X el Sabio (UAX), Villanueva de la Cañada, Madrid, Spain.
- Medical Oncology, Hospital Universitario Lucus Augusti, Lugo, Spain.
- Medical Oncology, Complejo Asistencial Universitario de León, León, Spain.
- Medical Oncology, Hospital General Universitario Dr. Balmis, Alicante, Spain.
- Universidad Alfonso X el Sabio (UAX), Villanueva de la Cañada, Madrid, Spain; Medical Oncology, Hospital Universitario Severo Ochoa, Madrid, Spain.
Förderung
- Fundacion Cientifica de la Asociacion Espanola Contra el Cancer
- Horizon 2020 Framework Programme
- European Regional Development Fund
- Gobierno de Espana Ministerio de Ciencia e Innovacion
- European Commission
- Albert Einstein Cancer Center
- Santander Universities
- Community of Madrid
Zitieren
APA
Martínez-Toledo, C., Jiménez-Meseguer, M., Molina-Alejandre, M., Calvo, V., Collazo-Lorduy, A., Sierra-Rodero, B., Blanco, M., Martínez Cutillas, M., Gil-González, Á., Gutiérrez-Escobedo, J. M., Vázquez Estévez, S., Fernández Núñez, N., Diz-Taín, P., Garrido Onecha, M. L., Martínez-Banaclocha, N., Peña, E., López Martín, A., Peña-Cabia, S., Sequero-López, S., …, & Provencio, M. (2026). Early pembrolizumab plasma levels as a prognostic biomarker in real-world NSCLC patients. Pharmacological Research, 228, 108232. https://doi.org/10.1016/j.phrs.2026.108232
Vancouver
Martínez-Toledo C, Jiménez-Meseguer M, Molina-Alejandre M, Calvo V, Collazo-Lorduy A, Sierra-Rodero B, et al. Early pembrolizumab plasma levels as a prognostic biomarker in real-world NSCLC patients. Pharmacological Research. 2026;228:108232. doi:10.1016/j.phrs.2026.108232
BibTeX
@article{MartnezToledo2026,
author = {Martínez-Toledo, Cristina and Jiménez-Meseguer, María and Molina-Alejandre, Marta and Calvo, Virginia and Collazo-Lorduy, Ana and Sierra-Rodero, Belén and Blanco, Mariola and Martínez Cutillas, Marta and Gil-González, Ángeles and Gutiérrez-Escobedo, Juan Manuel and Vázquez Estévez, Sergio and Fernández Núñez, Natalia and Diz-Taín, Pilar and Garrido Onecha, María Luisa and Martínez-Banaclocha, Natividad and Peña, Elena and López Martín, Ana and Peña-Cabia, Silvia and Sequero-López, Silvia and Rogado, Jacobo and Sánchez-Hernández, Alfredo and Coves Sarto, Juan and Sala González, Ángeles and Mielgo, Xabier and García Marrero, Rosa D and García-Grande, Aránzazu and Cruz-Bermúdez, Alberto and Provencio, Mariano},
title = {Early pembrolizumab plasma levels as a prognostic biomarker in real-world NSCLC patients},
journal = {Pharmacological Research},
year = {2026},
volume = {228},
pages = {108232},
doi = {10.1016/j.phrs.2026.108232}
}
EUVIMED